Kala Pharmaceuticals (KALA) Reports In-Line Q1 EPS, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. STZ
3. APLD
4. CRGY
5. PEP
6. DVN
7. ANGO
8. RMR
9. LULU
10. SPCX

Go back to Kala Pharmaceuticals (KALA) Reports In-Line Q1 EPS, Revenues Beat

Kala Pharmaceuticals Reports First Quarter 2019 Financial Results

May 9, 2019 7:00 AM EDT

Conference Call and Webcast Today at 8:00 a.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ: KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the first quarter ended March 31, 2019.

We are pleased with our results during the first quarter of 2019, particularly as it relates to the launch of INVELTYS, said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. We have received feedback from physicians that... More